

**IMPORTANT SAFETY INFORMATION ABOUT XELJANZ/XELJANZ XR (TOFACITINIB), OLUMIANT (BARICITINIB) AND RINVOQ (UPADACITINIB)**

Dear Member,

Your health is important to us. On September 1st, 2021, the U.S. Food and Drug Administration (FDA) announced a drug safety announcement.\* It is regarding new warnings associated with Xeljanz/Xeljanz XR (tofacitinib), Olumiant (baricitinib) and Rinvoq (upadacitinib).

If you are currently being treated with Xeljanz/Xeljanz XR (tofacitinib), Olumiant (baricitinib) or Rinvoq (upadacitinib), please contact your doctor to discuss your treatment.

We are writing this letter to give you information. This should not replace your doctor's advice. Only your doctor can decide what drugs are right for you.

Thank you,

Doctors HealthCare Plans, Inc.

4140\_RXDRUGSAFETY\_C

**ATENCIÓN:** Si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 786-460-3427 o 833-342-7463(TTY: 711).

\*<https://www.fda.gov/safety/medical-product-safety-information/janus-kinase-jak-inhibitors-drug-safety-communication-fda-requires-warnings-about-increased-risk>